Patients with type A aortic dissection have 3-fold higher risk of stroke in long-term: JAHA

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-11-09 03:30 GMT   |   Update On 2022-11-09 07:58 GMT

Taiwan: Type A aortic dissection (TAAD) patients versus aortic disease-free individuals are at increased long-term risk of stroke, both hemorrhagic and ischemic, research published in the Journal of the American Heart Association has stated.Type A aortic dissection (TAAD) patients were associated with a >3‐fold higher stroke risk than those without aortic disease for a mean follow-up...

Login or Register to read the full article

Taiwan: Type A aortic dissection (TAAD) patients versus aortic disease-free individuals are at increased long-term risk of stroke, both hemorrhagic and ischemic, research published in the Journal of the American Heart Association has stated.

Type A aortic dissection (TAAD) patients were associated with a >3‐fold higher stroke risk than those without aortic disease for a mean follow-up period of ≈5.71 years. According to the study authors, this is the first cohort study examining the association between TAAD and long-term stroke risk. "The trend of increased stroke risk was consistent across subgroups stratified by sex; age, antiplatelet use; and history of hypertension, dyslipidemia, or diabetes," they wrote in their study.

Type A aortic dissection among the most life‐threatening cardiovascular diseases (CVDs). In recent years, with advances in surgical repair techniques, the 3-year survival rate of TAAD patients has increased to 90.5%. However, they are shown to be a high short‐term risk of stroke but whether TAAD patients are at increased long‐term stroke risk remains unknown. To address this knowledge gap, Jin‐Yi Hsu, Tzu Chi University, Hualien, Taiwan, and colleagues aimed to examine whether TAAD patients have an increased long‐term risk of stroke on the basis of nationwide longitudinal data in Taiwan.

For this purpose, the researchers conducted a nationwide retrospective cohort study using Taiwan's National Health Insurance Research Database. They performed inverse probability of treatment weighting to balance patient characteristics between the groups. The Cox proportional hazards model, was used to determine the hazard ratios (HRs). The study's primary outcome was the development of stroke, irrespective of subtype.

The study demonstrated the following findings:

  • 3556 and 7023 patients were grouped into the TAAD and aortic disease–free cohorts, respectively, after the inverse probability of treatment weighting. These patients were followed for a mean period of 5.71 years.
  • Compared with the aortic disease-free cohort, the HRs for overall, hemorrhagic , and ischemic strokes in the TAAD cohort were 3.01, 2.32, and 3.18 respectively.
  • Analyses stratified by age; sex; antiplatelet use; and hypertension, diabetes, or dyslipidemia history revealed consistent trends of higher stroke risk in TAAD patients.

"Our results showed that TAAD patients are at increased long-term risk of strokes, both hemorrhagic and ischemic," the authors concluded. "Further research is warranted to develop optimal strategies for stroke prevention in these patients."

The findings provide physicians with more evidence for the requirement for intensive follow‐up and control of aggressive risk factors for modifiable stroke risk factors in Type A aortic dissection (TAAD) patients.

Reference:

Hsu JY, Liu PP, Liu AB, Huang HK, Loh CH. Long-Term Risks of Stroke in Patients With Type A Aortic Dissection: A Nationwide Cohort Study. J Am Heart Assoc. 2022 Nov 3:e027178. doi: 10.1161/JAHA.122.027178. Epub ahead of print. PMID: 36326053.

Tags:    
Article Source : Journal of the American Heart Association

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News